Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
April 13, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee...
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
April 12, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
March 30, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety Committee to review cohort four data – expect...
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
March 29, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 29, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
March 08, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Independent Safety Committee unanimously recommends cohort four (RECCE® 327 at 1,000mg) to commence; a 20-fold increase from cohort one dose (50mg)Cohort four subjects recruited - RECCE®...
Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
February 23, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well toleratedMilestone achieved with 10 total subjects dosed, maximizing...
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
February 08, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well tolerated Minimum recruited subjects met (7); additional three (3) at this...
Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
January 19, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Seven subjects in cohort two intravenously dosed with RECCE® 327 (R327) at 150mg met all endpoints - indicating R327 is safe and well toleratedIndependent Safety Committee clears third...
Recce Pharmaceuticals Announces Positive Safety Data from First Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
January 10, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Nine subjects in cohort one intravenously dosed with RECCE® 327 at 50mg meets all endpoints, indicating to be safe and well toleratedIndependent Safety Committee clears second study...
Recce Pharmaceuticals Announces Patients to be Dosed in a Phase I Intravenous Clinical Trial of RECCE® 327
December 15, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 healthy subjects recruited for Phase I clinical trialDosing in subjects will commence December 16, 2021RECCE® 327 (R327) may be the only clinical-stage anti-infective in development...